Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 1, 2015, Pages 245-252

  Cahill, Katherine N ^a,b   Bensko, Jillian C ^a,b   Boyce, Joshua A ^a,b   Laidlaw, Tanya M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aspirin desensitization; Aspirin exacerbated respiratory disease; asthma; cysteinyl leukotrienes; eosinophils; nasal polyps; prostaglandin D2; Samter triad; thromboxane; urinary eicosanoids

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 9,15 DIOXO 11ALPHA HYDROXY 13,14 DIHYDRO 2,3,4,5 TETRANOR PROSTAN 1,20 DIOIC ACID; 9ALPHA,11BETA DIHYDROXY 15 OXO 2,3,18,19 TETRANORPROST 5 ENE 1,20 DIOIC ACID; ACETYLSALICYLIC ACID; ICOSANOID; LEUKOTRIENE E4; MONTELUKAST; PROSTAGLANDIN D2; THROMBOXANE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BASOPHIL COUNT; BLOOD; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; ICOSANOID METABOLISM; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; MALE; METABOLITE; NAUSEA; PAIN; PROSTAGLANDIN RELEASE; URINALYSIS; URINE LEVEL; BASOPHIL; CHEMICALLY INDUCED; DRUG HYPERSENSITIVITY; EOSINOPHIL; IMMUNOLOGY; MIDDLE AGED; RESPIRATORY TRACT DISEASE; URINE;

ADULT; ASPIRIN; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; EICOSANOIDS; EOSINOPHILS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RESPIRATORY TRACT DISEASES;

EID: 84920389743     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.07.031     Document Type: Article

References (51)

1. M. Kupczyk, Z. Kurmanowska, I. Kuprys-Lipinska, M. Bochenska-Marciniak, and P. Kuna Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge Respir Med 104 2010 1404 1409
2. K. Sladek, and A. Szczeklik Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma Eur Respir J 6 1993 391 399
3. D.D. Stevenson, R.A. Simon, and D.A. Mathison Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges J Allergy Clin Immunol 66 1980 82 88
4. M. Swierczynska-Krepa, M. Sanak, Grazyna Bochenek, P. Strek, A. Cmiel, and A. Gielicz Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study J Allergy Clin Immunol 134 2014 883 890
5. 4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits Proc Natl Acad Sci U S A 90 1993 2015 2019
6. 4 Proc Natl Acad Sci U S A 91 1994 7663 7667
7. 4 synthase Proc Natl Acad Sci U S A 91 1994 9745 9749
8. M. Kumlin, F. Stensvad, L. Larsson, B. Dahlén, and S.E. Dahlén Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans Clin Exp Allergy 25 1995 467 479
9. Y. Kanaoka, A. Maekawa, and K.F. Austen Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand J Biol Chem 288 2013 10967 10972
10. K.R. Lynch, G.P. O'Neill, Q. Liu, D.S. Im, N. Sawyer, and K.M. Metters Characterization of the human cysteinyl leukotriene cysLT1 receptor Nature 399 1999 789 793
11. H.M. Sarau, R.S. Ames, J. Chambers, C. Ellis, N. Elshourbagy, and J.J. Foley Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor Mol Pharmacol 56 1999 657 663
12. C.E. Heise, B.F. O'Dowd, D.J. Figueroa, N. Sawyer, T. Nguyen, and D.S. Im Characterization of the human cysteinyl leukotriene 2 receptor J Biol Chem 275 2000 30531 30536
13. P.J. Daffern, D. Muilenburg, T.E. Hugli, and D.D. Stevenson Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses J Allergy Clin Immunol 104 1999 559 564
14. A. White, E. Ludington, P. Mehra, D.D. Stevenson, and R.A. Simon Effect of leukotriene modifier drugs on the safety of oral aspirin challenges Ann Allergy Asthma Immunol 97 2006 688 693
15. C. Benyahia, I. Gomez, L. Kanyinda, K. Boukais, C. Danel, and G. Leséche PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? Pulm Pharmacol Ther 25 2012 115 118
16. C. Feng, E.M. Beller, S. Bagga, and J.A. Boyce Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses Blood 107 2006 3243 3250
17. M. Luo, S.M. Jones, S.M. Phare, M.J. Coffey, M. Peters-Golden, and T.G. Brock Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523 J Biol Chem 279 2004 41512 41520
18. R.C. Beasley, R.L. Featherstone, M.K. Church, P. Faggerty, J.G. Varley, and A. Harris Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction J Appl Physiol 66 1989 1685 1693
19. C.C. Hardy, C. Robinson, A.E. Tattersfield, and S.T. Holgate The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men N Engl J Med 311 1984 209 213
20. K. Cheng, T.J. Wu, K.K. Wu, C. Sturino, K. Metters, and K. Gottesdiener Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682 6687
21. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, and Y. Takamori Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J Exp Med 193 2001 255 261
22. L. Xue, M. Salimi, I. Panse, J.M. Mjosberg, A.N. McKenzie, and H. Spits Prostaglandin D activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on T2 cells J Allergy Clin Immunol 133 2014 1184 1194
23. 2 metabolites Allergol Int 61 2012 393 403
24. G. Bochenek, K. Nagraba, E. Nizankowska, and A. Szczeklik A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge J Allergy Clin Immunol 111 2003 743 749
25. A. Szczeklik, K. Sladek, R. Dworski, E. Bizankowska, J. Soja, and J. Sheller Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics Am J Respir Crit Care Med 154 1996 1608 1614
26. E. Macy, J.A. Bernstein, M.C. Castells, S.M. Gawchik, T.H. Lee, and R.A. Settipane Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper Ann Allergy Asthma Immunol 98 2007 172 174
27. National Asthma Education and Prevention Program, third expert panel on the diagnosis and management of asthma Expert panel report 3: guidelines for the diagnosis and management of asthma 2007 National Heart, Lung, and Blood Institute Bethesda Available at http://www.ncbi.nlm.nih.gov/books/NBK7232/
28. T.M. Laidlaw, M.S. Kidder, N. Bhattacharyya, W. Xing, S. Shen, and G.L. Milne Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes Blood 119 2012 3790 3798
29. J.D. Morrow, and T.A. Minton Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry J Chromatogr 612 1993 179 185
30. J.A. Awad, J.D. Morrow, K. Takahashi, and L.J. Roberts 2nd Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma J Biol Chem 268 1993 4161 4169
31. J.D. Morrow, C. Guzzo, G. Lazarus, J.A. Oates, and L.J. Roberts 2nd Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2 J Invest Dermatol 104 1995 937 940
32. P.E. Christie, P. Tagari, A.W. Ford-Hutchinson, S. Charlesson, P. Chee, and J.P. Arm Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects Am Rev Respir Dis 143 1991 1025 1029
33. A. Szczeklik, K. Sladek, R. Dworski, E. Nizankowska, J. Soja, and J. Sheller Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics Am J Respir Crit Care Med 154 1996 1608 1614
34. 4 excretion in aspirin-induced asthma Ann Allergy Asthma Immunol 80 1998 171 176
35. E.B. Brandt, R.T. Strait, D. Hershko, Q. Wang, E.E. Muntel, and T.A. Scribner Mast cells are required for experimental oral allergen-induced diarrhea J Clin Invest 112 2003 1666 1677
36. L. Mastalerz, M. Sanak, A. Gawlewicz-Mroczka, A. Gielicz, and A. Szczeklik Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity Thorax 63 2008 27 34
37. R.U. Lee, A.A. White, D. Ding, A.B. Dursun, K.M. Woessner, and R.A. Simon Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease Ann Allergy Asthma Immunol 105 2010 130 135
38. T. Liu, T.M. Laidlaw, H.R. Katz, and J.A. Boyce Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes Proc Natl Acad Sci U S A 110 2013 16987 16992
39. W.L. Song, J. Stubbe, E. Ricciotti, N. Alamuddin, S. Ibrahim, and I. Crichton Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans J Clin Invest 122 2012 1459 1468
40. C.C. Hardy, P. Bradding, C. Robinson, and S.T. Holgate Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma J Appl Physiol 64 1988 1567 1574
41. T. Yoshimura, M. Yoshikawa, N. Otori, S. Haruna, and H. Moriyama Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma Allergol Int 57 2008 429 436
42. A. Szczeklik, R.J. Gryglewski, E. Olszewski, A. Dembinska-Kiec, and G. Czerniawska-Mysik Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps Pharamacol Res Commun 9 1977 415 425
43. W.L. Smith, E.A. Meade, and D.L. Dewitt Interaction of PGH synthase isozymes-1 and -2 with nonsteroidal anti-inflammatory drugs Adv Exp Med Biol 400A 1997 189 196
44. A. Sousa, R. Pfister, P.E. Christie, S.J. Lane, S.M. Nasser, and M. Schmitz-Schumann Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma Thorax 52 1997 940 945
45. K.M. Woessner, R.A. Simon, and D.D. Stevenson The safety of celecoxib in patients with aspirin-sensitive asthma Arthritis Rheum 46 2002 2201 2206
46. S.M. Nasser, M. Patel, G.S. Bell, and T.H. Lee The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma Am J Respir Crit Care Med 151 1995 1326 1330
47. A. Szczeklik, R. Dworski, L. Mastalerz, A. Prokop, J. Sheller, and E. Nizankowska Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism Am J Respir Crit Care Med 158 1998 1168 1172
48. A.K. Larsson, A. Hagfjard, S.E. Dahlen, and M. Adner Prostaglandin D(2) induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig Eur J Pharmacol 669 2011 136 142
49. G. Bochenek, J. Kuschill-Dziurda, K. Szanfraniec, H. Plutecka, A. Szczeklik, and E. Nizankowska-Mogilnicka Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis J Clin Allergy Immunol 133 2014 98 103
50. S.L. Johnston, P.G. Bardin, J. Harrison, W. Ritter, J.R. Joubert, and S.T. Holgate The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations Br J Clin Pharmacol 34 1992 402 408
51. W.W. Busse, S.E. Wenzel, E.O. Meltzer, E.M. Kerwin, M.C. Liu, and N. Zhang Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients J Allergy Clin Immunol 131 2013 339 345